Safety and Efficacy of NY-ESO-1 Antigen-specific T-cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.

Akira Kawai Mikiya Ishihara Tomoki Nakamura Shigehisa Kitano Shintaro Iwata Kohichi Takada Makoto Emori Koji Kato Makoto Endo Yoshihiro Matsumoto Shigeki Kakunaga Eiichi Sato Yoshihiro Miyahara Kunihiko Morino Shinya Tanaka Shuichi Takahashi Fujio Matsuo Akihiko Matsumine Shinichi Kageyama Takafumi Ueda

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Adoptive immunotherapy with TBI-1301 to selectively target NY-ESO-1 positive tumor cells appears to be a promising strategy for the treatment of advanced or recurrent synovial sarcoma with acceptable toxicity.

Keyphrases

clinical trial
traumatic brain injury
cell therapy
oxidative stress
genome wide
randomized controlled trial
study protocol
phase ii
bone marrow
mesenchymal stem cells
severe traumatic brain injury
double blind
phase iii
binding protein
genome wide identification
placebo controlled